INDICATIONS AND USAGE

SERQUEL is indicated for the treatment of schizophrenia.
The efficacy of SERQUEL is noticated for the treatment of schizophrenia.
The efficacy of SERQUEL is noticephrenia in schizophrenia was established in short-term (6-week) controlled trials of schizophrenia inpatients (See CLINICAL PHARIMACOLLOGY).
The effectiveness of SERQUEL in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use SERQUELE for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient
CONTRAINDICATIONS

SERQUEL is contraindicated in individuals with a known hypersensitivity to this medication or any of its ingredients.
WARNINGS

Neurolabil Mallingant Containers (MARIMOS)

Meurlegile Malignant Syndrome: (MMS) A potentially fatal symptom complex sometimes referred to as Neurolegite Malignant Syndrome (MMS) has been reported in association with administration of antipsychtotic drugs. Two ossels cases of MMS [22387 (0.1%)] have been reported in clinical trials with SEROQUEL. Clinical association of MMS are hyperprised, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, disphoresis, and cardiac chyshyrthmia). Additional signar gain clinical evidence dreatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure. The diagnosis: evaluation of patients with this syndrome is complicated in rarving at adiagnosis, it is important to exclude cases where the clinical presentation includes our inadequately treated extrapyramidal signs and symptomis (PS). Other important or inadequately treated extrapyramidal signs and symptomis (PS). Other important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important or inadequately treated extrapyramidal signs and symptomis (PS). Dither important and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment are available. There is no general agreement about specific pharmacological treatment regimens for MMS. It a patient of the patient should be presented in the contract of the patient should be presented in the contract of the patient should permit an extra structure of the patient should permit should permit should be presented in the patient should permit should permit should

have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. SEROOUEL and other antipsychotic drugs should be used cautously in patients at risk for aspiration pneumonia. Suicide: The possibility of a suicide attention. For a procession of high risk patients should accompany drug therapy. Prescriptors for SEROOUEL should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. Use in Patients with good patient management in order to reduce the risk of overdose. Use in Patients with concomitant systemic illnesses is limited. SEROOUEL in patients with concomitant systemic illnesses is limited. SEROOUEL in patients with concomitant systemic illnesses is limited. SEROOUEL in patients with concomitant systemic illnesses is limited. SEROOUEL in patients with concomitant systemic illnesses because with these diagnoses were excluded from the state of superent accordance for phramosopogial brainers of years and processing and processing of the phramosopogial brainers of years and processing and processing

SENOVOEL: "Quoespare introduces and the secrete in milk of treated animals during lactation. It is not known if SEROULEL was excreted in human milk. It is recommended that women receiving SEROULEL is excreted in human milk. It is recommended that women receiving SEROULEL is excreted in human milk. It is recommended that women receiving SEROULEL in pediatric patients have not been established. Gertatric Use: Of the approximately 2400 patients in clinical studies with SEROULEL. 8% (190) were 65 years of age or over. In general, there was no indication of any different tolerability of SEROULEL in the adderly compared to younger adults. Nevertheless, the presence of factors that might decrease pharmacokinetic clerance, increase the pharmacokynamic response to SEROULEL, or scales profer tolerance or or orthostass, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dissing period in the elderly. The mean plasma clerance of SEROULEL was reduced by 30% to 50% in elderly patients when compared to vouncer galatric. younger patients.
ADVERSE REACTIONS

Adverse Events Occurring at an Incidence of 1% or More Among SEROQUEL
Treated Patients in Short-Term, Placebo-Controlled Trials: The most commonly
beserved adverse events associated with the use of SEROQUEL in incidence of 5% or
greater) and observed at a rate on SEROQUEL at least twice that of placedo very
replaced and observed at a rate on SEROQUEL at least twice that of placedo very
replaced and observed and of the server place of the server placedo the read of 1% or more, and were at least as frequent among SEROQUEL treated patients in
3- to 6-week placebo-controlled trials.

Body as a Whitel. Headzich, Astron. Additional pain Bock open placebo treated patients in
3- to 6-week placebo-controlled trials.

Body as a Whitel. Headzich, Astron. Beach pages and placebo-controlled pla



WELL!

Efficacy you look for in an atypical antipsychotic

ACCEPTED!

An excellent side-effect profile

- the risk of tardive dyskinesia, seizures, and






25 mg, 100 mg, 200 mg & 300 mg tablets

Treatment patients can LIVE with!

References: 1. Small JG, Hirsch SR, Arvanitis LA, et al, and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54:549-557. 2. Arvanitis LA, Miller BG, and the SEROQUEL Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42:233-246. 3. Borison RL, Arvanitis LA, Miller BG. ICl 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 1996;16:158-169. 4. Data on file, Study S91, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 5. SEROQUEL® (quetiapine fumarate) Prescribing Information, Rev 1/01, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.



© 2001 AstraZeneca Pharmaceuticals LP. SEROQUEL is a registered trademark of the AstraZeneca group of companies. https://d**AstraZeneca/Priamaceuticals**:EP Published antine by laimb buge runive is it pless rescribing Information on following page.

www.SEROOUEL.com